P
Prothena Corporation plc (PRTA)
NMS – Real vaqt narxi. Valyuta: USD
9.43
-0.24 (-2.48%)
Yopilishda: May 12, 2026, 4:00 PM EDT
9.73
+0.30 (3.18%)
Bozor oldidan: May 13, 2026, 4:08 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
9.43
-0.24 (-2.48%)
Yopilishda: May 12, 2026, 4:00 PM EDT
9.73
+0.30 (3.18%)
Bozor oldidan: May 13, 2026, 4:08 AM EDT
Prothena Corporation plc, kechki bosqichdagi klinik biotexnologiya kompaniyasi, oqsil disfunksiyasidan kelib chiqqan kasalliklarni davolash uchun yangi terapiyalarni kashf qilish va ishlab chiqishga qaratilgan. Uning mahsulotlar qatoriga Parkinson kasalligi va boshqa sinukleinopatiyalarni davolash uchun 3-bosqich klinik sinovlarda bo'lgan Prasinezumab, tadqiqotdagi insonlashtirilgan monoklonal antitel kiradi. Kompaniya, shuningdek, transtiretin amiloidozini davolash uchun 3-bosqich klinik sinovlarda bo'lgan Coramitug, tadqiqotdagi antitel; Altsgeymer kasalligini davolash uchun 2-bosqich klinik sinovlarda bo'lgan anti-tau antitel BMS-986446; neyrodegenerativ kasalliklarni davolash uchun 1-bosqich klinik sinovlarda bo'lgan PRX019, tadqiqotdagi antitel; va Altsgeymer kasalligini davolash uchun preklinik sinovlarda bo'lgan Dual Aβ-Tau Vaccine PRX123ni ishlab chiqadi. Bundan tashqari, u amyotrofik lateral sklerozni davolash uchun TDP-43 CYTOPE; Altsgeymer kasalligini davolash uchun 1-bosqich klinik sinovlarda bo'lgan keyingi avlod anti-Aβ antitel PRX012; va Altsgeymer kasalligini davolash uchun preklinik dastur PRX012-TfRni o'z ichiga olgan kashfiyot va kechki preklinik bosqich dasturlarini ishlab chiqadi. U F. Hoffmann-La Roche Ltd. va Hoffmann-La Roche Inc. bilan α-sinukleinni, shu jumladan prasinezumabni nishonga olgan antitelarni ishlab chiqish va tijoratlashtirish bo'yicha litsenziyalash, ishlab chiqish va tijoratlashtirish shartnomasiga; va tau, TDP-43ni nishonga olgan antitelarni ishlab chiqish va tijoratlashtirish bo'yicha Bristol Myers Squibb bilan master hamkorlik shartnomasiga ega. Prothena Corporation plc 2012-yilda tashkil etilgan va Dublin, Irlandiyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Chad H. Swanson Ph.D. | Chief Development Officer |
| Dr. Gene G. Kinney Ph.D. | President, CEO & Director |
| Dr. Wagner M. Zago Ph.D. | Chief Scientific Officer |
| Mr. Brandon S. Smith | Chief Operating Officer |
| Mr. Mark C. Johnson C.F.A. | Vice President of Investor Relations |
| Mr. Michael J. Malecek | Chief Legal Officer & Company Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | prta-20260331.htm |
| 2026-03-27 | DEFA14A | ef20069090_defa14a.htm |
| 2026-02-27 | POS AM | d922560dposam.htm |
| 2026-02-27 | 8-K | prta-20260227.htm |
| 2026-02-19 | 8-K | prta-20260219.htm |
| 2025-12-12 | 8-K | prta-20251210.htm |
| 2025-11-19 | 8-K | prta-20251119.htm |
| 2025-11-06 | DEFA14A | d922240ddefa14a.htm |
| 2025-10-07 | DEF 14A | ny20053507x2_def14a.htm |
| 2025-09-25 | PRE 14A | ny20053507x1_pre14a.htm |
| Mr. Tran B. Nguyen M.B.A. | Chief Financial Officer |
| Ms. Annie Evans Kingston | Chief Strategy Officer |
| Ms. Karin L. Walker CPA | Chief Accounting Officer & Controller |
| Phillip Dolan | Sr. Director & Head of Exploratory Research |